These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 16134447)
41. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Pliszka S; J Am Acad Child Adolesc Psychiatry; 2007 Jul; 46(7):894-921. PubMed ID: 17581453 [TBL] [Abstract][Full Text] [Related]
45. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962 [TBL] [Abstract][Full Text] [Related]
47. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Pae CU Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730 [No Abstract] [Full Text] [Related]
48. Attention deficit disorder: not just for children. Clarke S; Heussler H; Kohn MR Intern Med J; 2005 Dec; 35(12):721-5. PubMed ID: 16313548 [TBL] [Abstract][Full Text] [Related]
49. Risperidone-to-methylphenidate switch reaction in children: three cases. Sabuncuoglu O J Psychopharmacol; 2007 Mar; 21(2):216-9. PubMed ID: 17329303 [TBL] [Abstract][Full Text] [Related]
50. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death. Knight M Pediatrics; 2007 Jan; 119(1):154-5. PubMed ID: 17200281 [No Abstract] [Full Text] [Related]
52. Acute dyskinesia on starting methylphenidate after risperidone withdrawal. Hollis CP; Thompson A Pediatr Neurol; 2007 Oct; 37(4):287-8. PubMed ID: 17903675 [TBL] [Abstract][Full Text] [Related]
53. Case of a 67-year-old woman diagnosed with ADHD successfully treated with methylphenidate. da Silva MA; Louza M J Atten Disord; 2008 May; 11(6):623. PubMed ID: 18417727 [No Abstract] [Full Text] [Related]
54. ADHD drugs and cardiovascular risk. Wojnowski L N Engl J Med; 2006 May; 354(21):2296-8; author reply 2296-8. PubMed ID: 16729376 [No Abstract] [Full Text] [Related]
56. Attention deficit hyperactivity disorder and substance use disorders. Szobot CM; Bukstein O Child Adolesc Psychiatr Clin N Am; 2008 Apr; 17(2):309-23, viii. PubMed ID: 18295148 [TBL] [Abstract][Full Text] [Related]
57. [How to treat ADHD/DAMP? Is there a conclusive answer? A critical survey of the MTA trial?]. Hansen L; Thomsen PH Ugeskr Laeger; 2005 Nov; 167(48):4555-9. PubMed ID: 16324436 [TBL] [Abstract][Full Text] [Related]
58. Beyond the 'typical' patient: treating attention-deficit/hyperactivity disorder in preschoolers and adults. Vaughan BS; Wetzel MW; Kratochvil CJ Int Rev Psychiatry; 2008 Apr; 20(2):143-9. PubMed ID: 18386204 [TBL] [Abstract][Full Text] [Related]
59. [The use of methylphenidate in children with ADHD]. Lauth B Laeknabladid; 2007 Dec; 93(12):823. PubMed ID: 18057471 [No Abstract] [Full Text] [Related]